• Other
  • Exited

Motus is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases. Its lead product candidate, relamorelin, is a potent, best-in-class, Phase 2 ghrelin agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes, and other GI functional disorders. Motus believes this  product candidate has the potential to treat gastrointestinal conditions for which there are currently limited therapeutic options.